Tisagenlecleucel
| Tisagenlecleucel | |
|---|---|
| Term | Tisagenlecleucel |
| Short definition | tisagenlecleucel - (pronounced) (TIH-suh-jen-LEK-loo-sel) drug used to treat adults with certain types of B-cell non-Hodgkin's lymphoma and people up to 25 years of age with certain types of B-cell acute lymphoblastic leukemia. It is also being studied in the treatment of other types of cancer. |
| Type | Cancer terms |
| Specialty | Oncology |
| Language | English |
| Source | NCI |
| Comments | |
tisagenlecleucel - (pronounced) (TIH-suh-jen-LEK-loo-sel) drug used to treat adults with certain types of B-cell non-Hodgkin's lymphoma and people up to 25 years of age with certain types of B-cell acute lymphoblastic leukemia. It is also being studied in the treatment of other types of cancer. Tisagenlecleucel is made using a patient's T cells (a type of cell in the immune system). A gene for a special receptor called the chimeric antigen receptor (CAR) is added to the T cells in the laboratory. Large numbers of these modified T cells, known as CAR T cells, are cultivated in the laboratory and given to the patient by infusion. Tisagenlecleucel attaches to a protein called CD19 found on some leukemia and lymphoma cells. This helps the body's immune system kill cancer cells. Tisagenlecleucel is a form of CAR T cell therapy. Also called Kymriah
External links
- Medical encyclopedia article on Tisagenlecleucel
- Wikipedia's article - Tisagenlecleucel
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski